Quick Answer
Pacira BioSciences, Inc. reported R&D Expense of $117.31 million for fiscal year 2025.
Pacira BioSciences, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $117.31M | +43.8% |
| 2024 | $81.58M | +7.0% |
| 2023 | $76.26M | -10.1% |
| 2022 | $84.80M | +52.7% |
| 2021 | $55.55M | -6.5% |
| 2020 | $59.42M | -17.6% |
| 2019 | $72.12M | +29.5% |
| 2018 | $55.69M | -2.8% |
| 2017 | $57.29M | +25.4% |
| 2016 | $45.68M | +59.4% |
| 2015 | $28.66M | +53.0% |
| 2014 | $18.73M | -13.1% |
| 2013 | $21.56M | +117.0% |
| 2012 | $9.94M | -33.2% |
| 2011 | $14.87M | -20.2% |
| 2010 | $18.63M | -29.0% |
| 2009 | $26.23M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $25.97M | +35.9% | -7.9% |
| June 30, 2025 | $28.20M | +38.7% | +11.3% |
| March 31, 2025 | $25.34M | +39.0% | +32.7% |
| September 30, 2024 | $19.10M | -8.3% | -6.1% |
| June 30, 2024 | $20.34M | +8.0% | +11.5% |
| March 31, 2024 | $18.24M | +6.4% | -12.4% |
| September 30, 2023 | $20.83M | +7.3% | +10.7% |
| June 30, 2023 | $18.82M | -28.4% | +9.8% |
- Pacira BioSciences, Inc. showed an increase of +43.8% in R&D Expense compared to the prior fiscal year.
- Over the 2009–2025 period, Pacira BioSciences, Inc.’s r&d expense has grown by 347.2% (from $26.23 million to $117.31 million).
- The most recent figure is from Pacira BioSciences, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: